PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. M...

Full description

Saved in:

Bibliographic Details
Published in	Acta pharmacologica Sinica Vol. 34; no. 2; pp. 255 - 261
Main Authors	Pei, Qi, Huang, Qiong, Yang, Guo-ping, Zhao, Ying-chun, Yin, Ji-ye, Song, Min, Zheng, Yi, Mo, Zhao-hui, Zhou, Hong-hao, Liu, Zhao-qian
Format	Journal Article
Language	English
Published	London Nature Publishing Group UK 01.02.2013 Nature Publishing Group
Subjects	Aged Biomedical and Life Sciences Biomedicine Blood Glucose - analysis Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Female Genotype Humans Hypoglycemic Agents - therapeutic use Immunology Internal Medicine Male Medical Microbiology Middle Aged Original original-article Pharmacology/Toxicology Polymorphism, Single Nucleotide PPAR gamma - genetics Receptor-Like Protein Tyrosine Phosphatases, Class 2 - genetics Thiazolidinediones - therapeutic use Vaccine PPAR-γ2 rs1801282 pioglitazone type 2 diabetes genetic polymorphisms PTPRD rs17584499 Chinese Han population
Online Access	Get full text
ISSN	1671-4083 1745-7254 1745-7254
DOI	10.1038/aps.2012.144

Cover

Abstract	Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po ) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268–0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135–3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.
AbstractList	Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po ) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268–0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135–3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population.AIMTo investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population.One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined.METHODSOne hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined.The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype.RESULTSThe PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype.Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.CONCLUSIONDiabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.
Author	Yin, Ji-ye Zhao, Ying-chun Song, Min Zheng, Yi Pei, Qi Yang, Guo-ping Huang, Qiong Liu, Zhao-qian Zhou, Hong-hao Mo, Zhao-hui
Author_xml	– sequence: 1 givenname: Qi surname: Pei fullname: Pei, Qi organization: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Department of Pharmacy, Third Xiangya Hospital, Central South University – sequence: 2 givenname: Qiong surname: Huang fullname: Huang, Qiong organization: Institute of Clinical Pharmacology, Anhui Medical University – sequence: 3 givenname: Guo-ping surname: Yang fullname: Yang, Guo-ping organization: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University – sequence: 4 givenname: Ying-chun surname: Zhao fullname: Zhao, Ying-chun organization: Osteoporosis Research Center, Creighton University – sequence: 5 givenname: Ji-ye surname: Yin fullname: Yin, Ji-ye organization: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University – sequence: 6 givenname: Min surname: Song fullname: Song, Min organization: Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University – sequence: 7 givenname: Yi surname: Zheng fullname: Zheng, Yi organization: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University – sequence: 8 givenname: Zhao-hui surname: Mo fullname: Mo, Zhao-hui email: easd04mzh@126.com organization: Department of Endocrinology, Third Xiangya Hospital, Central South University – sequence: 9 givenname: Hong-hao surname: Zhou fullname: Zhou, Hong-hao organization: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University – sequence: 10 givenname: Zhao-qian surname: Liu fullname: Liu, Zhao-qian email: liuzhaoqian63@126.com organization: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/23147557$$D View this record in MEDLINE/PubMed
BookMark	eNqFkctu1DAUhi1URC-wY428owsy-JY42SBVUwqVKjGqytryxCczLolt7AQ0fS3eg2eqRzPlJhCrY8nfOf_5_3OMDpx3gNBzSmaU8Pq1DmnGCGUzKsQjdESlKAvJSnGQ35WkhSA1P0THKd0SwhmnzRN0mIuQZSmP0KfF4uy6-P6NYe0MXtwsrs_xChzg4PvN4GNY2zQkbF3XT-BawOMmAGbYWL2EERIOerTgxvQSR0jBu5QRj4P1q96O-i7vmpvxfG2dfooed7pP8GxfT9DHi7c38_fF1Yd3l_Ozq6LlXIqi5BVplqwyddcJUTWiajuyBElNqWXFSd3pqgNpNAjDTWkY7WpKq4aIkhgiCD9BxW7u5ILefNV9r0K0g44bRYnahqZyaGobmsqhZf7Njg_TcgDTZjtR_-zx2qrff5xdq5X_ogTJulTmAaf7AdF_niCNarCphb7XDvyUFGW1qBht-Ha3F79q_RB5uEgG2A5oo08pQqfanONo_Vba9v9y8OqPpv8Y3geUMuZWENWtn6LLN_k7fw9hAr1_
CitedBy_id	crossref_primary_10_1016_j_lfs_2013_12_232 crossref_primary_10_1093_ajcn_nqaa037 crossref_primary_10_3390_biom13121791 crossref_primary_10_2147_DMSO_S390752 crossref_primary_10_1016_j_smallrumres_2016_09_020 crossref_primary_10_18632_oncotarget_4092 crossref_primary_10_1002_dmrr_3109 crossref_primary_10_1111_joim_12330 crossref_primary_10_2217_pgs_14_162 crossref_primary_10_1080_14656566_2021_1967319 crossref_primary_10_32345_2664_4738_1_2_2019_04 crossref_primary_10_2337_dc13_1276 crossref_primary_10_3390_pharmaceutics15061778 crossref_primary_10_1007_s40200_020_00720_z crossref_primary_10_2217_pme_15_11 crossref_primary_10_1016_j_mgene_2017_12_002 crossref_primary_10_1007_s00125_020_05181_w crossref_primary_10_3389_fendo_2020_499788 crossref_primary_10_1007_s13410_016_0517_2 crossref_primary_10_1136_egastro_2024_100159 crossref_primary_10_1111_jcmm_12417 crossref_primary_10_1007_s00438_023_02011_7 crossref_primary_10_23736_S2724_542X_23_02996_6 crossref_primary_10_1038_s41598_020_69363_7 crossref_primary_10_1159_000519382 crossref_primary_10_1080_14622416_2024_2430163 crossref_primary_10_2174_1573399814666180912130401 crossref_primary_10_2337_dci20_0022 crossref_primary_10_1007_s40484_020_0209_2 crossref_primary_10_1016_j_gde_2018_02_005 crossref_primary_10_1002_jcla_22340 crossref_primary_10_1038_nrendo_2016_51 crossref_primary_10_2217_pgs_2017_0009 crossref_primary_10_1097_FPC_0000000000000265 crossref_primary_10_1155_2013_376454 crossref_primary_10_1186_s13046_019_1469_4 crossref_primary_10_3389_fendo_2022_919087 crossref_primary_10_1002_cpt_1484
Cites_doi	10.2337/diacare.28.5.1139 10.1139/o04-120 10.1038/nrm2039 10.1038/347645a0 10.1007/s001250051268 10.1055/s-2002-35421 10.1016/j.bmcl.2010.08.130 10.1006/bbrc.1997.7798 10.1016/S0149-2918(03)80068-1 10.1038/3099 10.1210/jcem.87.6.8567 10.2337/diabetes.50.10.2309 10.1016/0168-8227(94)90151-1 10.1530/eje.0.1410090 10.1074/jbc.270.22.12953 10.1016/j.metabol.2009.10.030 10.1006/bbrc.2000.2096 10.1073/pnas.92.25.11686 10.2217/pgs.09.82 10.1182/blood-2007-02-075911 10.1007/s00228-010-0882-6 10.1016/S0149-2918(02)85040-8 10.1016/j.ejphar.2011.09.158 10.1038/79216 10.1097/01.fpc.0000230112.96086.e0 10.1038/oby.2007.617 10.2165/00003495-200060020-00009 10.1146/annurev.biochem.70.1.341 10.2337/diacare.23.11.1605 10.1371/journal.pgen.1000847 10.1016/S1050-1738(02)00187-1 10.1111/j.1742-7843.2006.pto_437.x 10.2337/diacare.26.3.825 10.1038/sj.bjp.0706306 10.1016/j.clpt.2005.04.013 10.1111/j.1742-1241.2000.tb10937.x
ContentType	Journal Article
Copyright	CPS and SIMM 2013 Copyright © 2013 CPS and SIMM 2013 CPS and SIMM
Copyright_xml	– notice: CPS and SIMM 2013 – notice: Copyright © 2013 CPS and SIMM 2013 CPS and SIMM
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY
DOI	10.1038/aps.2012.144
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1745-7254
EndPage	261
ExternalDocumentID	10.1038/aps.2012.144 PMC4011617 23147557 10_1038_aps_2012_144
Genre	Clinical Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -05 -0E -Q- -SE -S~ .3N 0R~ 188 1OC 23M 2WC 31~ 36B 3V. 4.4 406 53G 5GY 5VR 5VS 6J9 70F 7X7 8-1 88E 8FI 8FJ 8R4 8R5 8RM 92M 9D9 9DE A8Z AACDK AANZL AASML AATNV AAXDM AAZLF ABAKF ABAWZ ABKZE ABUWG ABZZP ACAOD ACGFO ACGFS ACIWK ACKTT ACMJI ACPRK ACRQY ACXQS ACZOJ ADBBV ADFRT ADHDB ADRAZ AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AFBBN AFBPY AFKRA AFRAH AFSHS AFUIB AFZJQ AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJAOE AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS AXYYD BAWUL BBNVY BENPR BFHJK BHPHI BKKNO BPHCQ BVXVI C1A CAG CAJEE CCEZO CCPQU CHBEP CIEJG CO8 COF CS3 CW9 DIK DNIVK DPUIP E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FA0 FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GX1 HCIFZ HH5 HMCUK HYE HZI HZ~ IWAJR JSO JUIAU JZLTJ K97 KQ8 LGEZI LH4 LOTEE LW6 M1P M48 M7P MK0 NADUK NQJWS NXXTH O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q-- Q-4 Q2X R-E RNT RNTTT ROL RPM RT5 S.. SNX SNYQT SOHCF SRMVM SV3 SWTZT T8U TAOOD TBHMF TDRGL TEORI TR2 TSG U1F U1G U5E U5O UKHRP UZ5 ~88 ~NG AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION ESTFP PHGZM PHGZT PJZUB PPXIY PQGLB PUEGO SOJ CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC AFFHD UNPAY
ID	FETCH-LOGICAL-c3374-53609b26d8ff446946cf0be71d5a76308fa6fe7dae4d3d5d21f811690450d0403
IEDL.DBID	M48
ISSN	1671-4083 1745-7254
IngestDate	Wed Oct 29 12:04:45 EDT 2025 Tue Sep 30 16:43:02 EDT 2025 Wed Oct 01 10:09:01 EDT 2025 Thu Apr 03 06:53:46 EDT 2025 Wed Oct 01 02:45:55 EDT 2025 Thu Apr 24 22:57:21 EDT 2025 Fri Feb 21 02:38:48 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	PPAR-γ2 rs1801282 pioglitazone type 2 diabetes genetic polymorphisms PTPRD rs17584499 Chinese Han population
Language	English
License	http://www.springer.com/tdm
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3374-53609b26d8ff446946cf0be71d5a76308fa6fe7dae4d3d5d21f811690450d0403
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	https://proxy.k.utb.cz/login?url=https://www.nature.com/articles/aps2012144.pdf
PMID	23147557
PQID	1284621930
PQPubID	23479
PageCount	7
ParticipantIDs	unpaywall_primary_10_1038_aps_2012_144 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4011617 proquest_miscellaneous_1284621930 pubmed_primary_23147557 crossref_citationtrail_10_1038_aps_2012_144 crossref_primary_10_1038_aps_2012_144 springer_journals_10_1038_aps_2012_144
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	20130200
PublicationDateYYYYMMDD	2013-02-01
PublicationDate_xml	– month: 2 year: 2013 text: 20130200
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: United States
PublicationTitle	Acta pharmacologica Sinica
PublicationTitleAbbrev	Acta Pharmacol Sin
PublicationTitleAlternate	Acta Pharmacol Sin
PublicationYear	2013
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Ludovico, Pellegrini, Di Paola, Minenna, Mastroianno, Cardellini (CR30) 2007; 15 Huang, Yin, Dai, Wu, Chen, Deng (CR24) 2010; 66 Masugi, Tamori, Mori, Koike, Kasuga (CR26) 2000; 268 Gillies, Dunn (CR17) 2000; 60 Kang, Park, Kim, Kim, Ahn, Cha (CR8) 2005; 78 Willson, Lambert, Kliewer (CR15) 2001; 70 Herz, Johns, Reviriego, Grossman, Godin, Duran (CR21) 2003; 25 Zimmet (CR16) 2002; 12 Lawrence, Reckless (CR22) 2000; 54 Altshuler, Hirschhorn, Klannemark, Lindgren, Vohl, Nemesh (CR2) 2000; 26 Daily, Aquilante (CR35) 2009; 10 Deeb, Fajas, Nemoto, Pihlajamaki, Mykkanen, Kuusisto (CR5) 1998; 20 Lehmann, Moore, Smith-Oliver, Wilkison, Willson, Kliewer (CR25) 1995; 270 Matsuda, Kuzuya (CR1) 1994; 26 Boyle, King, Olansky, Marchetti, Lau, Magar (CR19) 2002; 24 Issemann, Green (CR3) 1990; 347 Yen, Beamer, Negri, Silver, Brown, Yarnall (CR7) 1997; 241 Chagnon, Uetani, Tremblay (CR11) 2004; 82 Miyazaki, Mahankali, Matsuda, Mahankali, Hardies, Cusi (CR18) 2002; 87 Pulido, Serra-Pages, Tang, Streuli (CR31) 1995; 92 Brunmair, Gras, Neschen, Roden, Wagner, Waldhausl (CR32) 2001; 50 Wu, Ouyang, Wu, Wang, Wen, Xia (CR34) 2005; 146 Bluher, Lubben, Paschke (CR29) 2003; 26 Auwerx (CR4) 1999; 42 Hsieh, Lin, Tien, Tu, Hsiao, Chang (CR27) 2010; 59 Jaakkola, Laitila, Neuvonen, Backman (CR36) 2006; 99 Hamann, Munzberg, Buttron, Busing, Hinney, Mayer (CR6) 1999; 141 Bhattarai, Kafle, Hwang, Ham, Lee, Park (CR33) 2010; 20 Tsai, Yang, Chen, Chuang, Lu, Chang (CR9) 2010; 6 Aronoff, Rosenblatt, Braithwaite, Egan, Mathisen, Schneider (CR20) 2000; 23 Kang, Park, Kim, Ahn, Nam, Cha (CR14) 2005; 28 Toscano, Klein, Blievernicht, Schaeffeler, Saussele, Raimundo (CR13) 2006; 16 Namvaran, Azarpira, Rahimi-Moghaddam, Dabbaghmanesh (CR28) 2011; 671 Tonks (CR10) 2006; 7 Scherbaum, Goke (CR23) 2002; 34 Kawase, Akatsuka, Torikai, Morishima, Oka, Tsujimura (CR12) 2007; 110 JM Lawrence (BFaps2012144_CR22) 2000; 54 PJ Boyle (BFaps2012144_CR19) 2002; 24 A Matsuda (BFaps2012144_CR1) 1994; 26 FJ Tsai (BFaps2012144_CR9) 2010; 6 D Altshuler (BFaps2012144_CR2) 2000; 26 Y Miyazaki (BFaps2012144_CR18) 2002; 87 MC Hsieh (BFaps2012144_CR27) 2010; 59 PS Gillies (BFaps2012144_CR17) 2000; 60 ES Kang (BFaps2012144_CR8) 2005; 78 J Masugi (BFaps2012144_CR26) 2000; 268 MJ Chagnon (BFaps2012144_CR11) 2004; 82 J Auwerx (BFaps2012144_CR4) 1999; 42 M Bluher (BFaps2012144_CR29) 2003; 26 CJ Yen (BFaps2012144_CR7) 1997; 241 S Aronoff (BFaps2012144_CR20) 2000; 23 I Issemann (BFaps2012144_CR3) 1990; 347 Q Huang (BFaps2012144_CR24) 2010; 66 BR Bhattarai (BFaps2012144_CR33) 2010; 20 A Hamann (BFaps2012144_CR6) 1999; 141 ES Kang (BFaps2012144_CR14) 2005; 28 C Toscano (BFaps2012144_CR13) 2006; 16 R Pulido (BFaps2012144_CR31) 1995; 92 B Brunmair (BFaps2012144_CR32) 2001; 50 NK Tonks (BFaps2012144_CR10) 2006; 7 O Ludovico (BFaps2012144_CR30) 2007; 15 M Herz (BFaps2012144_CR21) 2003; 25 T Jaakkola (BFaps2012144_CR36) 2006; 99 EB Daily (BFaps2012144_CR35) 2009; 10 JM Lehmann (BFaps2012144_CR25) 1995; 270 SS Deeb (BFaps2012144_CR5) 1998; 20 Y Wu (BFaps2012144_CR34) 2005; 146 T Kawase (BFaps2012144_CR12) 2007; 110 WA Scherbaum (BFaps2012144_CR23) 2002; 34 P Zimmet (BFaps2012144_CR16) 2002; 12 TM Willson (BFaps2012144_CR15) 2001; 70 F Namvaran (BFaps2012144_CR28) 2011; 671 8524829 - Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11686-90 7768881 - J Biol Chem. 1995 Jun 2;270(22):12953-6 10652233 - Biochem Biophys Res Commun. 2000 Feb 5;268(1):178-82 12610044 - Diabetes Care. 2003 Mar;26(3):825-31 15997237 - Br J Pharmacol. 2005 Sep;146(2):234-43 10983737 - Drugs. 2000 Aug;60(2):333-43; discussion 344-5 16867170 - Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51 12809958 - Clin Ther. 2003 Apr;25(4):1074-95 9425261 - Biochem Biophys Res Commun. 1997 Dec 18;241(2):270-4 20809084 - Eur J Clin Pharmacol. 2010 Dec;66(12):1207-15 7705195 - Diabetes Res Clin Pract. 1994 Dec 16;26(2):137-43 11952022 - Clin Ther. 2002 Mar;24(3):378-96 2129546 - Nature. 1990 Oct 18;347(6294):645-50 20045142 - Metabolism. 2010 Aug;59(8):1139-44 17495182 - Obesity (Silver Spring). 2007 May;15(5):1076-81 15855579 - Diabetes Care. 2005 May;28(5):1139-44 11220991 - Int J Clin Pract. 2000 Nov;54(9):614-8 11574413 - Diabetes. 2001 Oct;50(10):2309-15 16084854 - Clin Pharmacol Ther. 2005 Aug;78(2):202-8 11092281 - Diabetes Care. 2000 Nov;23(11):1605-11 9806549 - Nat Genet. 1998 Nov;20(3):284-7 12536122 - Trends Cardiovasc Med. 2002 Nov;12(8):354-62 10447513 - Diabetologia. 1999 Sep;42(9):1033-49 17057753 - Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 17409267 - Blood. 2007 Aug 1;110(3):1055-63 20174558 - PLoS Genet. 2010 Feb;6(2):e1000847 20850970 - Bioorg Med Chem Lett. 2010 Nov 15;20(22):6758-63 10973253 - Nat Genet. 2000 Sep;26(1):76-80 12050251 - J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91 19761371 - Pharmacogenomics. 2009 Sep;10(9):1489-510 12439788 - Horm Metab Res. 2002 Oct;34(10):589-95 21968139 - Eur J Pharmacol. 2011 Dec 5;671(1-3):1-6 11395411 - Annu Rev Biochem. 2001;70:341-67 15674434 - Biochem Cell Biol. 2004 Dec;82(6):664-75 17001295 - Pharmacogenet Genomics. 2006 Oct;16(10):755-66 10407229 - Eur J Endocrinol. 1999 Jul;141(1):90-2
References_xml	– volume: 28 start-page: 1139 year: 2005 end-page: 44 ident: CR14 article-title: The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/diacare.28.5.1139 – volume: 82 start-page: 664 year: 2004 end-page: 75 ident: CR11 article-title: Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases publication-title: Biochem Cell Biol doi: 10.1139/o04-120 – volume: 7 start-page: 833 year: 2006 end-page: 46 ident: CR10 article-title: Protein tyrosine phosphatases: from genes, to function, to disease publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm2039 – volume: 347 start-page: 645 year: 1990 end-page: 50 ident: CR3 article-title: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators publication-title: Nature doi: 10.1038/347645a0 – volume: 42 start-page: 1033 year: 1999 end-page: 49 ident: CR4 article-title: PPARgamma, the ultimate thrifty gene publication-title: Diabetologia doi: 10.1007/s001250051268 – volume: 34 start-page: 589 year: 2002 end-page: 95 ident: CR23 article-title: Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study publication-title: Horm Metab Res doi: 10.1055/s-2002-35421 – volume: 54 start-page: 614 year: 2000 end-page: 8 ident: CR22 article-title: Pioglitazone publication-title: Int J Clin Pract – volume: 20 start-page: 6758 year: 2010 end-page: 63 ident: CR33 article-title: Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-gamma activators publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2010.08.130 – volume: 241 start-page: 270 year: 1997 end-page: 4 ident: CR7 article-title: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1997.7798 – volume: 25 start-page: 1074 year: 2003 end-page: 95 ident: CR21 article-title: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80068-1 – volume: 20 start-page: 284 year: 1998 end-page: 7 ident: CR5 article-title: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity publication-title: Nat Genet doi: 10.1038/3099 – volume: 87 start-page: 2784 year: 2002 end-page: 91 ident: CR18 article-title: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.87.6.8567 – volume: 50 start-page: 2309 year: 2001 end-page: 15 ident: CR32 article-title: Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression publication-title: Diabetes doi: 10.2337/diabetes.50.10.2309 – volume: 26 start-page: 137 year: 1994 end-page: 43 ident: CR1 article-title: Relationship between obesity and concordance rate for type 2 (non-insulin-dependent) diabetes mellitus among twins publication-title: Diabetes Res Clin Pract doi: 10.1016/0168-8227(94)90151-1 – volume: 141 start-page: 90 year: 1999 end-page: 2 ident: CR6 article-title: Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects publication-title: Eur J Endocrinol doi: 10.1530/eje.0.1410090 – volume: 270 start-page: 12953 year: 1995 end-page: 6 ident: CR25 article-title: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) publication-title: J Biol Chem doi: 10.1074/jbc.270.22.12953 – volume: 59 start-page: 1139 year: 2010 end-page: 44 ident: CR27 article-title: Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus publication-title: Metabolism doi: 10.1016/j.metabol.2009.10.030 – volume: 268 start-page: 178 year: 2000 end-page: 82 ident: CR26 article-title: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2000.2096 – volume: 92 start-page: 11686 year: 1995 end-page: 90 ident: CR31 article-title: The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.92.25.11686 – volume: 10 start-page: 1489 year: 2009 end-page: 510 ident: CR35 article-title: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies publication-title: Pharmacogenomics doi: 10.2217/pgs.09.82 – volume: 110 start-page: 1055 year: 2007 end-page: 63 ident: CR12 article-title: Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen publication-title: Blood doi: 10.1182/blood-2007-02-075911 – volume: 66 start-page: 1207 year: 2010 end-page: 15 ident: CR24 article-title: Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-010-0882-6 – volume: 24 start-page: 378 year: 2002 end-page: 96 ident: CR19 article-title: Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records publication-title: Clin Ther doi: 10.1016/S0149-2918(02)85040-8 – volume: 671 start-page: 1 year: 2011 end-page: 6 ident: CR28 article-title: Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2011.09.158 – volume: 26 start-page: 76 year: 2000 end-page: 80 ident: CR2 article-title: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes publication-title: Nat Genet doi: 10.1038/79216 – volume: 16 start-page: 755 year: 2006 end-page: 66 ident: CR13 article-title: Impaired expression of CYP2D6 in intermediate metabolizers carrying the 41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events publication-title: Pharmacogenet Genomics doi: 10.1097/01.fpc.0000230112.96086.e0 – volume: 15 start-page: 1076 year: 2007 end-page: 81 ident: CR30 article-title: Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2007.617 – volume: 60 start-page: 333 year: 2000 end-page: 43 ident: CR17 article-title: Pioglitazone publication-title: Drugs doi: 10.2165/00003495-200060020-00009 – volume: 70 start-page: 341 year: 2001 end-page: 67 ident: CR15 article-title: Peroxisome proliferator- activated receptor gamma and metabolic disease publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.70.1.341 – volume: 23 start-page: 1605 year: 2000 end-page: 11 ident: CR20 article-title: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group publication-title: Diabetes Care doi: 10.2337/diacare.23.11.1605 – volume: 6 start-page: e1000847 year: 2010 ident: CR9 article-title: A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000847 – volume: 12 start-page: 354 year: 2002 end-page: 62 ident: CR16 article-title: Addressing the insulin resistance syndrome: a role for the thiazolidinediones publication-title: Trends Cardiovasc Med doi: 10.1016/S1050-1738(02)00187-1 – volume: 99 start-page: 44 year: 2006 end-page: 51 ident: CR36 article-title: Pioglitazone is metabolised by CYP2C8 and CYP3A4 : potential for interactions with CYP2C8 inhibitors publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2006.pto_437.x – volume: 26 start-page: 825 year: 2003 end-page: 31 ident: CR29 article-title: Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/diacare.26.3.825 – volume: 146 start-page: 234 year: 2005 end-page: 43 ident: CR34 article-title: Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706306 – volume: 78 start-page: 202 year: 2005 end-page: 8 ident: CR8 article-title: Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.04.013 – volume: 141 start-page: 90 year: 1999 ident: BFaps2012144_CR6 publication-title: Eur J Endocrinol doi: 10.1530/eje.0.1410090 – volume: 671 start-page: 1 year: 2011 ident: BFaps2012144_CR28 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2011.09.158 – volume: 54 start-page: 614 year: 2000 ident: BFaps2012144_CR22 publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2000.tb10937.x – volume: 50 start-page: 2309 year: 2001 ident: BFaps2012144_CR32 publication-title: Diabetes doi: 10.2337/diabetes.50.10.2309 – volume: 99 start-page: 44 year: 2006 ident: BFaps2012144_CR36 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2006.pto_437.x – volume: 110 start-page: 1055 year: 2007 ident: BFaps2012144_CR12 publication-title: Blood doi: 10.1182/blood-2007-02-075911 – volume: 15 start-page: 1076 year: 2007 ident: BFaps2012144_CR30 publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2007.617 – volume: 268 start-page: 178 year: 2000 ident: BFaps2012144_CR26 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2000.2096 – volume: 42 start-page: 1033 year: 1999 ident: BFaps2012144_CR4 publication-title: Diabetologia doi: 10.1007/s001250051268 – volume: 347 start-page: 645 year: 1990 ident: BFaps2012144_CR3 publication-title: Nature doi: 10.1038/347645a0 – volume: 60 start-page: 333 year: 2000 ident: BFaps2012144_CR17 publication-title: Drugs doi: 10.2165/00003495-200060020-00009 – volume: 92 start-page: 11686 year: 1995 ident: BFaps2012144_CR31 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.92.25.11686 – volume: 59 start-page: 1139 year: 2010 ident: BFaps2012144_CR27 publication-title: Metabolism doi: 10.1016/j.metabol.2009.10.030 – volume: 7 start-page: 833 year: 2006 ident: BFaps2012144_CR10 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm2039 – volume: 270 start-page: 12953 year: 1995 ident: BFaps2012144_CR25 publication-title: J Biol Chem doi: 10.1074/jbc.270.22.12953 – volume: 26 start-page: 137 year: 1994 ident: BFaps2012144_CR1 publication-title: Diabetes Res Clin Pract doi: 10.1016/0168-8227(94)90151-1 – volume: 66 start-page: 1207 year: 2010 ident: BFaps2012144_CR24 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-010-0882-6 – volume: 78 start-page: 202 year: 2005 ident: BFaps2012144_CR8 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.04.013 – volume: 28 start-page: 1139 year: 2005 ident: BFaps2012144_CR14 publication-title: Diabetes Care doi: 10.2337/diacare.28.5.1139 – volume: 34 start-page: 589 year: 2002 ident: BFaps2012144_CR23 publication-title: Horm Metab Res doi: 10.1055/s-2002-35421 – volume: 146 start-page: 234 year: 2005 ident: BFaps2012144_CR34 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706306 – volume: 24 start-page: 378 year: 2002 ident: BFaps2012144_CR19 publication-title: Clin Ther doi: 10.1016/S0149-2918(02)85040-8 – volume: 241 start-page: 270 year: 1997 ident: BFaps2012144_CR7 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1997.7798 – volume: 26 start-page: 76 year: 2000 ident: BFaps2012144_CR2 publication-title: Nat Genet doi: 10.1038/79216 – volume: 6 start-page: e1000847 year: 2010 ident: BFaps2012144_CR9 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000847 – volume: 10 start-page: 1489 year: 2009 ident: BFaps2012144_CR35 publication-title: Pharmacogenomics doi: 10.2217/pgs.09.82 – volume: 70 start-page: 341 year: 2001 ident: BFaps2012144_CR15 publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.70.1.341 – volume: 25 start-page: 1074 year: 2003 ident: BFaps2012144_CR21 publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80068-1 – volume: 26 start-page: 825 year: 2003 ident: BFaps2012144_CR29 publication-title: Diabetes Care doi: 10.2337/diacare.26.3.825 – volume: 20 start-page: 6758 year: 2010 ident: BFaps2012144_CR33 publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2010.08.130 – volume: 16 start-page: 755 year: 2006 ident: BFaps2012144_CR13 publication-title: Pharmacogenet Genomics doi: 10.1097/01.fpc.0000230112.96086.e0 – volume: 82 start-page: 664 year: 2004 ident: BFaps2012144_CR11 publication-title: Biochem Cell Biol doi: 10.1139/o04-120 – volume: 87 start-page: 2784 year: 2002 ident: BFaps2012144_CR18 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.87.6.8567 – volume: 20 start-page: 284 year: 1998 ident: BFaps2012144_CR5 publication-title: Nat Genet doi: 10.1038/3099 – volume: 23 start-page: 1605 year: 2000 ident: BFaps2012144_CR20 publication-title: Diabetes Care doi: 10.2337/diacare.23.11.1605 – volume: 12 start-page: 354 year: 2002 ident: BFaps2012144_CR16 publication-title: Trends Cardiovasc Med doi: 10.1016/S1050-1738(02)00187-1 – reference: 10407229 - Eur J Endocrinol. 1999 Jul;141(1):90-2 – reference: 19761371 - Pharmacogenomics. 2009 Sep;10(9):1489-510 – reference: 17057753 - Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 – reference: 7768881 - J Biol Chem. 1995 Jun 2;270(22):12953-6 – reference: 11952022 - Clin Ther. 2002 Mar;24(3):378-96 – reference: 20045142 - Metabolism. 2010 Aug;59(8):1139-44 – reference: 10652233 - Biochem Biophys Res Commun. 2000 Feb 5;268(1):178-82 – reference: 12610044 - Diabetes Care. 2003 Mar;26(3):825-31 – reference: 20809084 - Eur J Clin Pharmacol. 2010 Dec;66(12):1207-15 – reference: 9425261 - Biochem Biophys Res Commun. 1997 Dec 18;241(2):270-4 – reference: 20850970 - Bioorg Med Chem Lett. 2010 Nov 15;20(22):6758-63 – reference: 8524829 - Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11686-90 – reference: 12439788 - Horm Metab Res. 2002 Oct;34(10):589-95 – reference: 10983737 - Drugs. 2000 Aug;60(2):333-43; discussion 344-5 – reference: 15855579 - Diabetes Care. 2005 May;28(5):1139-44 – reference: 12809958 - Clin Ther. 2003 Apr;25(4):1074-95 – reference: 15674434 - Biochem Cell Biol. 2004 Dec;82(6):664-75 – reference: 17001295 - Pharmacogenet Genomics. 2006 Oct;16(10):755-66 – reference: 17495182 - Obesity (Silver Spring). 2007 May;15(5):1076-81 – reference: 2129546 - Nature. 1990 Oct 18;347(6294):645-50 – reference: 10447513 - Diabetologia. 1999 Sep;42(9):1033-49 – reference: 11092281 - Diabetes Care. 2000 Nov;23(11):1605-11 – reference: 16867170 - Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51 – reference: 20174558 - PLoS Genet. 2010 Feb;6(2):e1000847 – reference: 10973253 - Nat Genet. 2000 Sep;26(1):76-80 – reference: 11395411 - Annu Rev Biochem. 2001;70:341-67 – reference: 9806549 - Nat Genet. 1998 Nov;20(3):284-7 – reference: 11220991 - Int J Clin Pract. 2000 Nov;54(9):614-8 – reference: 12050251 - J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91 – reference: 15997237 - Br J Pharmacol. 2005 Sep;146(2):234-43 – reference: 17409267 - Blood. 2007 Aug 1;110(3):1055-63 – reference: 7705195 - Diabetes Res Clin Pract. 1994 Dec 16;26(2):137-43 – reference: 16084854 - Clin Pharmacol Ther. 2005 Aug;78(2):202-8 – reference: 11574413 - Diabetes. 2001 Oct;50(10):2309-15 – reference: 12536122 - Trends Cardiovasc Med. 2002 Nov;12(8):354-62 – reference: 21968139 - Eur J Pharmacol. 2011 Dec 5;671(1-3):1-6
SSID	ssj0032319
Score	2.2152052
Snippet	Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase... To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor...
SourceID	unpaywall pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	255
SubjectTerms	Aged Biomedical and Life Sciences Biomedicine Blood Glucose - analysis Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Female Genotype Humans Hypoglycemic Agents - therapeutic use Immunology Internal Medicine Male Medical Microbiology Middle Aged Original original-article Pharmacology/Toxicology Polymorphism, Single Nucleotide PPAR gamma - genetics Receptor-Like Protein Tyrosine Phosphatases, Class 2 - genetics Thiazolidinediones - therapeutic use Vaccine
SummonAdditionalLinks	– databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB7B9gAceD-Wl4wEy4FmSWI7iY8roKqQKFG1K5VT5MQ2RN0mUbMrtP1b_A9-E-O8ylIV9ZzJOLbH8_BMvgF4LVmktS-Yw3kkMEDhts2LEI4XoDkzGRo5aQPFLwfB_oJ9PuJHXaBYd2WVLaRlo6b76rD3sqp9Cz_G2LRS5jrsBBx97xHsLA7i2TcbVSFzHKvB3UQv2_Zo5ayrdHdpZBnYQi7fZjO3bdAFx_JifeSQJL0FN9ZFJTc_5XL5lx3auwNf-xm05SfH0_UqnWZn_4A7Xn2Kd-F255KSWUtxD67p4j5M4hbTerNL5ue_aNW7ZELic7TrzQM4juPZofP7l09koUg8jw8_EhRKTapyuTkpcRvz-qQmed8MhdhLX-KT_tKXdMiu9Vty2tbrIklJqrz8bvHDz0pklRek6fP9EBZ7n-Yf9p2ug4OTURqiANDAFakfqMgYjDsFCzLjpjr0FJeo2NzIyMDoUEnNFFVc-Z6JPJu4Y9xVqF7oIxgVOM4TIKk2IpOSMk4ZRmkYuQshXXzZC3UWsWgM7_o9TbIO3tx22VgmTZqdRgmub2IXGKMdNoY3A3XVwnpcQveqF48Ez51NpshCl-s6sXY9QHVP3TE8bsVl4IQ-Mws5D8cQbgnSQGAxvbefFPmPBtub2cSYh29OepFLOqVSX_KBk0Eg_zuTp1clfAY3_ablhy3ZeQ6j1elav0DHa5W-7E7bHw-jLU0 priority: 102 providerName: Unpaywall
Title	PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China
URI	https://link.springer.com/article/10.1038/aps.2012.144 https://www.ncbi.nlm.nih.gov/pubmed/23147557 https://www.proquest.com/docview/1284621930 https://pubmed.ncbi.nlm.nih.gov/PMC4011617 https://www.nature.com/articles/aps2012144.pdf
UnpaywallVersion	publishedVersion
Volume	34
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1745-7254 dateEnd: 20141231 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: HH5 dateStart: 19800101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1745-7254 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: KQ8 dateStart: 20090101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVEBS databaseName: EBSCO Food Science Source customDbUrl: eissn: 1745-7254 dateEnd: 20151130 omitProxy: false ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: A8Z dateStart: 20050101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/login.aspx?authtype=ip,uid&profile=ehost&defaultdb=fsr providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1745-7254 dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: DIK dateStart: 19800101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1745-7254 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1745-7254 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: AFBBN dateStart: 20050101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1745-7254 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: RPM dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 1745-7254 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: 7X7 dateStart: 20050101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1745-7254 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: BENPR dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1745-7254 dateEnd: 20251031 omitProxy: true ssIdentifier: ssj0032319 issn: 1671-4083 databaseCode: M48 dateStart: 20050101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB71cQAOiHeXx8pIEA40kMR2Eh8QWqBVhdRVtNqVllPkTRwakSbppisIf4v_wW9ivHmUpRRxjOI4cWbsmfGMvw_gmWS-Uo5gJue-wACFa5oXIUzbRXOWRGjkpA4Uj8fu0Yx9nPP5FnT18-0PrP4a2mk-qdkye_XtrH6LE_5Nc2Tcfy1LjbttOzpRaZRnpqaU0qnXll9jG3bRbAnN63DM-hQDRcdGNKclNZ8rZ21V_J8dbtqrS07o5VrKPqF6A66t8lLWX2WW_WazDm_BzdbZJKNGO27DlsrvgBE0aNX1PpleHL6q9olBggsc6_oufAmC0cT8-cMhMo9JMA0mHwiqmyJlkdWnBQoorU4rknY0J0Rv5xKHdNu5pMVsrV6QZVOJi00KUqbFZ40M_r3ArtKcrBm878Hs8GD6_shsuRnMiFIPRUtdSywcN_aTBCNKwdwosRbKs2Muccmy_ES6ifJiqVhMYx47duLbOiXHuBXjwkHvw06O79kDslCJiKSkjFOG8RfG5EJICx-2PRX5zB_Ay04CYdQCl2v-jCxcJ9CpH6K8Qi0vjGPYAJ73rcsGsOOKdk87YYY4o3SaROaqWFWhttguLuTUGsCDRrh9T6g0zOPcG4C3Ifa-gUbr3ryTpydr1G6mU142Pml0ChJ22n7FBxq9-vxzJA__YySP4Lqz5vHQdTiPYed8uVJP0Js6Xwxh25t7Q9h9dzAOJsP1HMGr2TgYffoFOj0i7A
linkProvider	Scholars Portal
linkToUnpaywall	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB7B9gAceD-Wl4wEy4FmSWI7iY8roKqQKFG1K5VT5MQ2RN0mUbMrtP1b_A9-E-O8ylIV9ZzJOLbH8_BMvgF4LVmktS-Yw3kkMEDhts2LEI4XoDkzGRo5aQPFLwfB_oJ9PuJHXaBYd2WVLaRlo6b76rD3sqp9Cz_G2LRS5jrsBBx97xHsLA7i2TcbVSFzHKvB3UQv2_Zo5ayrdHdpZBnYQi7fZjO3bdAFx_JifeSQJL0FN9ZFJTc_5XL5lx3auwNf-xm05SfH0_UqnWZn_4A7Xn2Kd-F255KSWUtxD67p4j5M4hbTerNL5ue_aNW7ZELic7TrzQM4juPZofP7l09koUg8jw8_EhRKTapyuTkpcRvz-qQmed8MhdhLX-KT_tKXdMiu9Vty2tbrIklJqrz8bvHDz0pklRek6fP9EBZ7n-Yf9p2ug4OTURqiANDAFakfqMgYjDsFCzLjpjr0FJeo2NzIyMDoUEnNFFVc-Z6JPJu4Y9xVqF7oIxgVOM4TIKk2IpOSMk4ZRmkYuQshXXzZC3UWsWgM7_o9TbIO3tx22VgmTZqdRgmub2IXGKMdNoY3A3XVwnpcQveqF48Ez51NpshCl-s6sXY9QHVP3TE8bsVl4IQ-Mws5D8cQbgnSQGAxvbefFPmPBtub2cSYh29OepFLOqVSX_KBk0Eg_zuTp1clfAY3_ablhy3ZeQ6j1elav0DHa5W-7E7bHw-jLU0
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PPAR-%CE%B32+and+PTPRD+gene+polymorphisms+influence+type+2+diabetes+patients%27+response+to+pioglitazone+in+China&rft.jtitle=Acta+pharmacologica+Sinica&rft.au=Pei%2C+Qi&rft.au=Huang%2C+Qiong&rft.au=Yang%2C+Guo-ping&rft.au=Zhao%2C+Ying-chun&rft.date=2013-02-01&rft.issn=1745-7254&rft.eissn=1745-7254&rft.volume=34&rft.issue=2&rft.spage=255&rft_id=info:doi/10.1038%2Faps.2012.144&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1671-4083&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1671-4083&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1671-4083&client=summon